Lantern (LTRN) Company Short-Term Debt

The current volume of short-term loans demonstrates the liability dynamics of Lantern Pharma Inc. (LTRN), while 0.00 captures the magnitude of this parameter. Lantern Pharma Inc. (LTRN) is reimagining oncology by applying machine learning to revive drugs through the identification of suitable patient groups. AI-driven supply chain optimization minimizes downtime risks, maintaining high margins. The strategy is based on partnerships with clinics to conduct budget-friendly trials.

Short-term debts reflect the total liabilities with maturities of up to one year, measuring current liquidity and the risk of working capital deficits. By analyzing the short-term debt trend, an investor assesses the reliance of Lantern Pharma Inc. (LTRN) on borrowed funds to finance AI developments in oncology, where the absence of a debt load confirms the sustainability of the payment model for clinical trial optimization services.